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A six-month, multicenter, randomized, open-label study was undertaken to determine whether renal function is improved using
reduced-exposure cyclosporine (CsA) versus standard-exposure CsA in 199 de novo heart transplant patients receiving everolimus
and steroids ± induction therapy. Mean C2 levels were at the low end of the target range in standard-exposure patients (n = 100)
and exceeded target range in reduced-exposure patients (n = 99) throughout the study. Mean serum creatinine at Month 6 (the
primaryendpoint)was141.0±53.1µmol/Linstandard-exposurepatientsversus130.1±53.7µmol/Linreduced-exposurepatients
(P = 0.093). The incidence of biopsy-proven acute rejection ≥3A at Month 6 was 21.0% (21/100) in the standard-exposure
group and 16.2% (16/99) in the reduced-exposure group (n.s.). Adverse events and infections were similar between treatment
groups. Thus, everolimus with reduced-exposure CsA resulted in comparable eﬃcacy compared to standard-exposure CsA. No
renal function beneﬁts were demonstrated; that is possibly related to poor adherence to reduced CsA exposure.
1.Introduction
One-yearsurvivalfollowingcardiactransplantationhasrisen
to approximately 85%, but long-term graft loss remains
a signiﬁcant problem with life expectancy 12 years after
transplantation remaining at only 50% [1]. Late-term com-
plicationsincluderenaldysfunction,malignancy,andcardiac
allograft vasculopathy (CAV) [1–3]. In a randomized trial
of everolimus versus azathioprine with standard-exposure
cyclosporine (CsA) and steroids in de novo heart transplant
recipients, use of everolimus signiﬁcantly reduced coronary
artery intimal proliferation, assessed by intravascular ultra-
sound, and the incidence of CAV up to 24 months [4, 5].
While everolimus is not associated with direct renal toxicity2 Journal of Transplantation
[6], it can potentiate CsA-related nephrotoxicity by P450
inhibition of CsA metabolism [7], and serum creatinine
levels were higher among patients receiving everolimus in
this study. This was found to be due to the use of ﬁxed-
dose administration of everolimus, instead of concentration-
controlled dosing, and because CsA was given at a standard
level of exposure [4]. Accordingly, everolimus dosing is
now based on blood concentration and reduced CsA dosing
is recommended in the maintenance phase to preserve
renal function in cardiac transplant recipients receiving
everolimus [8]. The eﬃcacy and safety of everolimus with
CNI minimization in maintenance thoracic transplant recip-
ients has been demonstrated in the prospective NOCTET
study [9] as well as in a single-arm pilot study [10, 11]
and two single-centre trials [12, 13]. To date, however, no
prospective study has attempted to determine the optimal
CsA exposure in de novo heart transplant patients receiving
everolimus. Moreover, no trial has assessed CsA exposure in
de novo everolimus-treated heart transplant recipients based
on C2 monitoring, which has been shown to lead to clinical
beneﬁts versus conventional C0 (trough level) monitoring
[14–20].
A six-month, multicentre, randomized, open-label study
was undertaken to determine whether renal function is
improved in de novo heart transplant patients receiving
reduced-exposure CsA versus standard-exposure CsA, based
on C2 monitoring, when administered in combination with
everolimus and steroids, with or without induction therapy.
2.MaterialsandMethods
2.1. Study Design. This was a six-month, multicentre,
prospective, randomized, open-label study (clintrials.gov
reference number NCT00098007) comparing renal function
(serum creatinine) in de novo heart transplant patients
receiving everolimus with either reduced-dose (RD) or
standard-dose (ST) CsA microemulsion (CsA-ME). Ran-
domization took place within 72 hours of transplantation
on a 1:1 basis using unique patient identiﬁcation numbers
assigned centrally. The study was conducted in accordance
with the ICH Harmonized Tripartite Guidelines for Good
Clinical Practice and the Declaration of Helsinki after
obtaining approval from the Institutional Review Board at
each centre and written informed consent from all patients.
2.2. Patients. The population comprised patients aged 18–
65 years receiving a primary heart transplant. Key exclusion
criteriaweredonor>60yearsofageorwithobviouscoronary
disease or known heart disease, cold ischaemia time >6
hours, receipt of a multiorgan transplant or any previ-
ous organ transplant, serum creatinine level >250µmol/L,
platelet count ≤50,000/mm3 or white blood cell count
of ≤2,500/mm3, panel reactive antibodies ≥25%, severe
hypercholesterolemia (≥9mmol/L), or hypertriglyceridemia
(≥8.5mmol/L).
2.3. Immunosuppression and Concomitant Medication. Cen-
tres were permitted to use antithymocyte globulin (ATG) or
Table 1: Demographics and baseline characteristics. Continuous
variables are shown as mean ± SD.
RD CsA(n = 99) ST CsA(n = 100)
Recipient age (years) 49.8 ±11.77 49.4 ±10.44
Female recipient 25 (25.3%) 22 (22.0%)
White recipient 79 (79.8%) 77 (77.0%)
End stage disease leading
to transplantation
Cardiomyopathy 49 (49.5%) 55 (55.0%)
Coronary artery disease 32 (32.3%) 30 (30.0%)
Other 18 (18.2%) 15 (15.0%)
Ventricular assist device 12 (12.1%) 8 (8.0%)
Panel reactive antibodies
(%)
0%–10% 84 (84.5%) 87 (87.0%)
>10% 1 (1.0%) 0
Missing 14 (14.1%) 13 (13.0%)
Donor age (years) 35.3±13.9 35.5±11.9
Female donor 24 (24.2%) 35 (35.0%)
Cytomegalovirus D+/R− 23 (23.2%) 17 (17.0%)
Cold ischaemia time
(hours) [mean ± SD] 2.8 ±1.13 .2 ±1.2
Diabetes 31 (31.3%) 31 (31.0%)
Hypertension 45 (45.5%) 53 (53.0%)
interleukin (IL)-2 receptor antagonist induction consistently
for all patients at that centre. CsA-ME (Neoral, Novartis,
Basel, Switzerland) was initiated at ≤12mg/kg/day, except
at centres using induction therapy, where local practice
for CsA-ME introduction was followed. The dose was
subsequently adjusted to maintain a predeﬁned target C2
rangebasedonpreviousstudiesofC2-basedCsA monitoring
in heart transplant recipients (19, 20). The CsA C2 target
range was 1000–1400ng/mL for all patients during the ﬁrst
two months after transplant, after which CsA targets were
lowered according to the randomized groups: ST group 800-
1200ng/mLduringMonths3–5and600–1000ng/mLduring
Month 6; RD group 600–800ng/mL during Month 3, 400-
600ng/mL during Months 4-5 and 300–500ng/mL during
Month 6. The CsA C2 levels were determined at study days
2, 3, 5, 8, 15, 22, and 30 during the ﬁrst month and monthly
thereafter.Everolimus(Certican,NovartisPharmaAG,Basel,
Switzerland) was initiated within 72 hours after transplant,
at an initial dose of 0.75mg b.i.d., titrated after Day 5.
Everolimus trough (C0) level was recorded on Day 5 post-
randomization, after which the dose was titrated to achieve
aC 0 level in the range 3–8ng/mL. Cytomegalovirus (CMV)
prophylaxis was to be applied as per local center practice.
2.4. Primary Endpoint and Statistical Analysis. The primary
endpointwasrenalfunctionatsixmonthsaftertransplant,as
measured by serum creatinine. This was compared between
treatmentgroupsusingthet-test(0.05one-sidedsigniﬁcance
level). A sample size of 200 patients (100 per treatment arm)
was estimated to have 82% power to detect a diﬀerenceJournal of Transplantation 3
Table 2: Immunosuppression. Continuous variables are shown as
mean ± SD.
RD CsA
(n = 99)
ST CsA
(n = 100)
Everolimus dose (mg/day)
Month 1 1.3 ±0.51 .4 ±0.6
Month 6 1.4 ±0.61 .3 ±0.5
Everolimus trough concentration
(ng/mL)
Month 1 5.8 ±3.65 .8 ±2.5
Month 6 4.8 ±1.75 .3 ±2.3
Cyclosporine dose (mg/kg/day)
Month 1 3.8 ±1.34 .0 ±1.4
Month 6 2.5 ±1.02 .8 ±0.8
Cyclosporine trough
concentration (ng/mL)
Months 1-2 195 ±78 209 ±87
Month 6 120 ±63 154 ±68
Cyclosporine C2 concentration
(ng/mL)
Months 1-2 742 ±272 693 ±244
Month 6 566 ±278 707 ±284
Steroid dosea 0.50 ±1.40 0.32 ±0.25
Induction therapy
Antithymocyte globulin 60 (60.6%) 61 (61.0%)
Interleukin-2 receptor
antagonist 21 (21.2%) 20 (20.0%)
aMean dose during Months 0–6.
Table 3: Incidence of eﬃcacy events at Month 6. HDC, haemody-
namic compromise.
RD CsA
(n = 99)
ST CsA
(n = 100)
Composite eﬃcacy failure
(BPAR ≥3A, acute rejection
associated with HDC, death,
graft loss/retransplant or lost
to followup)
26 (26.3%) 25 (25.0%)
BPAR ≥3A 16 (16.2%) 21 (21.0%)
Acute rejection associated
with HDC 3 (3.0%) 4 (4.0%)
Graft loss 1 (1.0%) 1 (1.0%)
Death 6 (6.1%) 3 (3.0%)
All diﬀerences were non-signiﬁcant.
of 22µmol/L in mean serum creatinine level at 6 months
post-transplant assuming that mean creatinine would be
177 ± 60µmol/L in the ST group and 155 ± 60µmol/L
in the RD group (t-test with 0.05 one-sided signiﬁcance
level).Threepreplannedsupportiveanalyseswereperformed
on renal function for the ITT population. One supportive
analysis was based on the “on-treatment” Month 6 renal
function value. An on-treatment observation was deﬁned
as a measurement obtained ≤2 days after discontinuation
Table 4: Incidence of infections and adverse events of interest.
RD CsA
(n = 99)
ST CsA
(n = 100)
Any adverse event, or infection
or serious adverse event 99 (100.0%) 100
(100.0%)
Infection
Any 52 (52.5%) 47 (47.0%)
Bacterial 29 (29.3%) 18 (18.0%)
Fungal 2 (2.0%) 7 (7.0%)
Viral 13 (13.1%) 7 (7.0%)
CMV 7 (7.1%) 3 (3.0%)
Other 5 (5.1%) 9 (9.0%)
Unknown 26 (26.3%) 27 (27.0%)
Anaemia 21 (21.2%) 16 (16.0%)
Thrombocytopenia 5 (5.1%) 6 (6.0%)
Leukopenia 12 (12.1%) 7 (7.0%)
Incision-site related wound
healing complications1 10 (9.9%) 8 (8.0%)
Cardiac tamponade2 7 (6.9%) 5 (5.0%)
Eﬀusion-related complications3 5( 5 % ) 8( 8 . 0 % )
1Wound healing complications associated with a surgical procedure that
were reported as serious adverse events.
2Three more cardiac tamponades occurred after iatrogenic myocardial
perforation during biopsy procedure (2 ST and 1 RD).
3Pleural and pericardial eﬀusions that were reported as serious adverse
events.
of randomized study medication. The other two supportive
analyses were performed for all patients alive at the Month
6 visit based on the following imputation methods for
missing renal function value: (i) last observation carried
forward (LOCF) and (ii) multiple imputation. Post hoc
analyses were performed in the patients who remained
within CsA C2 target ranges throughout the study. Between-
groupdiﬀerencesin eﬃcacyeventrateswerecomparedusing
the two-sided z-test.
3. Results
3.1. Patients. In total, 199 patients were enrolled, ran-
domized, and formed the ITT (intent-to-treat) and safety
populations, of whom 184 patients completed the six-
month study, 128 on study medication (Figure 1). Patient
characteristics were similar in the RD group (n = 99) and
the ST group (n = 100) except of a lower mean cold
ischemia time in the RD group (RD: 2.8 ± 1.1h versus ST:
3.2 ±1.2h; P = 0.027) (Table 1).
3.2. Immunosuppression and Concomitant Medication. Mean
everolimus trough levels remained within the target range
(3–8ng/mL) in both cohorts at all study visits. During
Months 1-2, mean CsA C2 levels were markedly below target
in both groups and, indeed, higher in the RD group than
the ST group (RD 742 ± 272ng/mL; ST 693 ± 244ng/mL).
Subsequently, the mean C2 levels exceeded target range in
the RD patients throughout the study and were near the4 Journal of Transplantation
100 ST CsA
199 randomized
99 RD CsA
34 discontinued study medication
21 adverse events
6 administrative problems
2 abnormal laboratory values
2 unsatisfactory therapeutic
1 protocol violation
1 consent withdrawn
1 death
37 discontinued study medication
25 adverse events
6 administrative problems
1 abnormal laboratory values
1 unsatisfactory therapeutic
1 protocol violation
1 lost to followup
2 deaths
6 discontinued study
1 consent withdrawal
3 deaths
2 no reason stated
9 discontinued study
2 lost to followup
6 deaths
1 no reason stated
94 completed study
(66 on study medication)
90 completed study
(62 on study medication)
effect effect
Figure 1: Patient disposition.
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Figure 2: CsA C2 level during the six-month study. Shaded areas
indicate target C2 ranges (hatched area, shared target to Day
59; dark area, reduced-CsA; light area, standard-CsA). Values are
shown as mean±SD (central laboratory results).
lower end of the target range in the ST cohort (Figure 2).
Mean steroid dose over the six-month study was similar in
both groups (Table 2, P = 0.23), as was the percentage of
patients that received induction therapy. Use of concomitant
medication that could potentially inﬂuence renal function,
including angiotensin converting enzyme inhibitors and
aldosteronereceptorblockers,wassimilarbetweentreatment
groups (data not shown). CMV prophylaxis was used in
42.4% of patients in the RD group and in 49% of patients
in the ST cohort.
3.3. Renal Function. Mean serum creatinine at baseline
was 111.6 ± 46.4µmol/L in the RD arm and 116.0 ±
47.0µmol/L in the ST group. At Month 6, mean serum
creatinine was lower in the RD group than in the ST cohort
but the diﬀerence was not signiﬁcant (130.1 ± 53.7µmol/L
versus141.0±53.1µmol/L, P = 0.093)(Figure 3).Themean
increase in serum creatinine from baseline to Month 6 was
15.9 ± 52.7µmol/Li nt h eR Dg r o u pc o m p a r e dt o2 7 .9 ±
64.0µmol/L in the ST arm (P = 0.102). Predeﬁned sup-
portive analyses to account for missing Month 6 creatinine
measurements showed a signiﬁcantly lower mean creatinine
level at Month 6 in the RD versus the ST group (LOCF:
RD 127.3µmol/L, ST 145.9µmol/L, P = 0.023; multiple
imputation, RD: 127.9µmol/L, ST 143.8µmol/L, P = 0.027).
Mean eGFR (MDRD) at Month 6 was similar in the RD
group (59.0 ± 23.2mL/min/1.73m2)a n dS Ta r m( 5 9 .5 ±
48.2mL/min/1.73m2). The decline in eGFR from baseline
was numerically lower in the RD group, but this change was
notstatisticallysigniﬁcant(−10.4±23.2v e r s us−12.9 ±33.8,
P = 0.298).
A post hoc analysis was performed to analyze the change
in renal function from baseline to Month 6 for patients who
receivedCsAreductionsasrequiredbyprotocol(RD,n = 20;
ST, n = 32). Whereas the mean change in creatinine from
baseline to Month 6 was 5.5 ± 45.1µmol/L in the RD group,
patients in the ST group had a mean increase in creatinine of
31.4±57.7µmol/L(P = 0.047).Thecorrespondingchangein
eGFRwas −8.9±18.6mL/min/1.73m2 intheRDgroupand
−14.0±36.3mL/min/1.73m2 in the ST cohort (P = 0.267).
3.4. Eﬃcacy. There was no signiﬁcant between-group diﬀer-
ence in the incidence of the composite endpoint at MonthJournal of Transplantation 5
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Figure 3: Serum creatinine during the six-month study (ITT
population). Values shown are mean ± SD.
6, or in any individual eﬃcacy component (Table 3). Across
the total population, the incidence of BPAR ≥3A was 18.6%
(37/199).TheincidenceofBPAR ≥3Awasnumericallylower
in the RD group among patients who received induction
(17/81 ST [21.0%] versus 12/81 RD [14.8%], n.s.) and
similar with both CsA regimens in the no-induction group
(4/19 ST [21.1%] and 4/18 RD [22.2%]). Three patients died
in the ST group (2 multiorgan failure and 1 unknown cause
with no suspected relation to study drug) and six patients in
theRDgroup(2sepsis,1encephalitis,1primarygraftfailure,
1 unknown cause with no suspected relation to study drug,
and1unknowncauseinapatientexperiencingsuddendeath
inwhomautopsyrevealedanaorticanastomosisleakthatthe
investigator suspected to have a relationship to study drug).
3.5. Safety. The type and incidence of adverse events and
infections was similar between treatment groups (Table 4).
Adverse events or infections with a suspected relation to
s t u d yd r u gw e r er e p o r t e di n5 9S Tp a t i e n t s( 5 9 . 0 % )a n d
58 RD patients (58.6%). Serious adverse events occurred
in 57 ST patients (57.0%) and in 60 RD patients (60.6%).
CMV infection (deﬁned as positive antigenemia and/or
PCRand/orseroconversionwithoutsignsand/orsymptoms)
occurred in three ST patients (3.0%) and seven RD patients
(7.1%). Renal failure and acute renal failure were reported
as an adverse event in 25 ST patients (25.0%) and 22
RD patients (22.2%). In >60% of cases renal failure was
diagnosed during the ﬁrst two weeks after transplantation
and resolved within four weeks. Twelve (12%) patients in
the ST group and thirteen (13.1%) recipients in the RD
grouprequiredtemporarydialysis.Five(5%)STpatientsand
seven (7.1%) RD patients discontinued study prematurely
due to renal failure/acute renal failure. Wound healing
complications relating to the surgical intervention were
reported as serious adverse events in eight (8.0%) and
ten (9.9%) patients in the ST and RD groups, respectively
(n.s.). One patient in the study experienced an episode
of pneumonitis, possibly induced by everolimus. There
were no marked diﬀerences in hematological or laboratory
parameters between treatment groups. From baseline to
Month 6, the mean change in total cholesterol, LDL-
cholesterol, HDL-cholesterol, and triglyceride concentration
in the ST and RD groups was 2.16mmol/L and 2.42mmol/L
(P = 0.25), 1.17mmol/L and 1.33mmol/L (P = 0.31),
0.61mmol/L and 0.55mmol/L (P = 0.77), and 0.76mmol/L
and 1.62mmol/L (P = 0.06), respectively. Twenty-one
patients (21.0%) and 25 patients (25.3%) in the ST and
RD groups, respectively, discontinued study medication
due to adverse events. Haematological disorders (mostly
leukopenia, thrombocytopenia, and anaemia) leading to
discontinuationwereobservedintwoSTpatients(2.0%)and
three RD patients (3.0%).
4. Discussion
The well-established nephrotoxicity associated with cal-
cineurin inhibitors has prompted the exploration of
immunosuppressive regimens that maintain low rejection
rates while minimizing deterioration of renal function. The
current study was undertaken to investigate whether a
reduction in CsA exposure, as monitored by C2 levels, in
combinationwitheverolimusandcorticosteroidswouldhelp
to preserve renal function following heart transplantation
without compromising protection against acute rejection
compared with standard CsA exposure. Throughout the
study, however, there was poor adherence to planned CsA
exposurelevelssuchthatalthougheﬃcacywasindeedsimilar
between treatment groups there was no signiﬁcant diﬀerence
in creatinine values at Month 6—the primary endpoint—or
in mean eGFR.
At all time points, fewer than half the patients were
within CsA C2 target range: in fact, the mean C2 level was
higherinMonth3thanduringMonths1-2despiteaplanned
decrease in C2 concentration, while at Month 6, the RD
group had only a 20% reduction in CsA exposure compared
to the ST group. Reasons for nonadherence to protocol-
speciﬁed target ranges lied in the investigator inexperience
with CsA C2 monitoring, the concern of CsA underexposure
and related rejection risk for the RD arm especially during
the ﬁrst month, and ﬁnally the concern of CsA overexposure
and previously described renal toxicity [4] in the ST arm.
In heart transplant recipients, the potential penalty of graft
loss and death in the setting of rejection is greater than
recurrent dialysis in renal transplant recipients with graft
loss, leading to greater caution about lowering immunosup-
pression. Moreover, if there were signs of rejection on the
latest endomyocardial biopsy, then the protocol stipulated
that the CsA dose was not to be reduced after Month 2.
With ∼40% of patients having Grade 1A rejection reported,
this frequently prevented lowering of CsA and hence lower
exposurelevels.Interestingly,inthesmallnumberofpatients
whose CsA C2 remained within target range, post hoc
analysis showed a smaller increase in serum creatinine from
baseline and improved eGFR in the RD group versus the ST
arm. The A2411 de novo heart transplant recipient study
compared everolimus with reduced exposure CsA to MMF6 Journal of Transplantation
with standard exposure CsA. The study did not achieve
demonstrationofnoninferiorrenalfunctionwitheverolimus
at Month 6 possibly related to a higher than targeted
CsA exposure in the everolimus arm [21]. Randomized,
multicenter studies recruiting large patient numbers across
diﬀerent study sites and countries are important to obtain
robust data on the eﬃcacy and safety of immunosuppressive
regimens; however, adherence to protocol speciﬁcations
can vary possibly reﬂecting diﬀerences in experience and
conﬁdence into the studied treatment regimen.
A second drawback was the six-month duration of the
study; with hindsight, a longer followup would have been
helpful. The six-month study period was selected based on
evidence from the large, prospective trial undertaken by
Eisen et al., in which signiﬁcant diﬀerences in renal function
were observed within the ﬁrst six months (indeed, by the
end of Month 1) in patients randomized to everolimus
with standard-dose CsA versus azathioprine-treated controls
[4]. Serum creatinine concentrations at Month 12 from 18
patients who continued the assigned regimen in an umbrella
protocol were reviewed. Mean serum creatinine was 116.1 ±
48.0µmol/LamongsevenpatientsintheRDarmand153.4±
29.2µmol/L among 11 patients randomized to the ST arm.
While this suggests beneﬁt of the RD regimen could be
maintained at Month 12, the small patient numbers mean
that this can only be speculation.
Although eﬃcacy was good, as indicated by a low rate
of BPAR ≥3A, and was not compromised in either the RD
group or among patients without induction therapy, the
overlap in CsA exposure between treatment groups does not
allow us to conﬁrm whether reduced CsA exposure provides
asimilarrateofrejectiontoastandardCsAregimen.Though
cross-studycomparisonsneedtobeinterpretedwithcaution,
it is noteworthy that rejection rates in the RD arm of this
s t u d yw e r ec o m p a r a b l et or a t e so fB P A R≥3A seen for
everolimus with standard CsA exposure in the earlier study
B253 (27.8% and 19.0% for everolimus 1.5mg and 3mg,
resp.).
In conclusion, everolimus with CsA C2 monitoring and
corticosteroidsresultedinalowrateofBPAR ≥3Awithgood
graft survival at six months and acceptable renal function
preservation in de novo heart transplant recipients. However,
poor adherence to the planned CsA exposure ranges meant
that the potential beneﬁt of CsA reduction could not
be evaluated. Regarding the design of future studies, the
simultaneous introduction of two novel procedures—in
this case CsA lowering and use of C2 monitoring—into a
clinical study protocol increases the risk of poor adherence
to the protocol. Future protocols should consider measures
to improve CsA exposure adherence. Further randomized
studies are required to clarify if renal function in de
novo heart transplant recipients can be preserved using a
combination of everolimus and reduced-exposure CsA.
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